TY  - JOUR
AU  - Taugner, Julian
AU  - Käsmann, Lukas
AU  - Eze, Chukwuka
AU  - Rühle, Alexander
AU  - Tufman, Amanda
AU  - Reinmuth, Niels
AU  - Duell, Thomas
AU  - Belka, Claus
AU  - Manapov, Farkhad
TI  - Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
JO  - Investigational new drugs
VL  - 39
IS  - 4
SN  - 1573-0646
CY  - Dordrecht [u.a.]
PB  - Springer Science + Business Media B.V
M1  - DKFZ-2021-00600
SP  - 1189-1196
PY  - 2021
N1  - 2021 Aug;39(4):1189-1196
AB  - The aim of this prospective study is to evaluate the clinical use and real-world efficacy of durvalumab maintenance treatment after chemoradiotherapy (CRT) in unresectable stage, locally advanced non-small cell lung cancer (NSCLC). All consecutive patients with unresectable, locally advanced NSCLC and PD-L1 expression (≥1
KW  - Checkpoint inhibition (Other)
KW  - Chemoradiotherapy (Other)
KW  - Non-small cell lung cancer (Other)
KW  - PD-L1 inhibitor (Other)
KW  - Treatment pattern (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:33704621
DO  - DOI:10.1007/s10637-021-01091-9
UR  - https://inrepo02.dkfz.de/record/167866
ER  -